Table 2
Risk of subjects developing new airways obstruction following treatment with unselective and selective topical β antagonist compared to controls
| Number of new TBA cases | Number of unexposed subjects (group C) | Unadjusted rate ratio (95% CI) | Adjusted hazard ratio (95% CI) | |
|---|---|---|---|---|
| TBA-U = unselective topical β antagonist treated subjects; TBA-S = selective topical β antagonist treated subjects. | ||||
| *p<0.01; **p<0.001. | ||||
| TBA-U treated subjects | 69/2321 (3.0%) | 112/9094 (1.2%) | 2.30** (1.69 to 3.12) | 2.22** (1.63 to 3.02) |
| TBA-S treated subjects | 12/324 (3.7%) | 3.06** (1.67 to 5.54) | 2.96** (1.63 to 5.36) | |
